ITK and T-cell non-Hodgkin lymphoma: Having demonstrated that OTX015 led to interleukin-2-inducible kinase (ITK) down-regulation and given that deregulated ITK signaling is pathogenetic in some T-cell lymphomas [31, 32], we tested the therapeutic efficacy of ibrutinib, a selective inhibitor of Bruton's tyrosine kinase/ITK as a single agent or in combination with OTX015.